Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Zynex

3 Medical Marvel Stocks to Buy for Success

The medical sector is thriving, given the growing healthcare expenditure and rapid technological adoption. Given the industry’s tailwinds, fundamentally sound medical stocks Cardinal Health (CAH), Fresenius (FSNUY), and Zynex (ZYXI) could be ideal buys for substantial returns. Keep Reading….

2 "B" Rated Medical Stocks to Buy Today, 1 to Closely Watch

2 "B" Rated Medical Stocks to Buy Today, 1 to Closely Watch

The medical industry is well-positioned for growth due to increased healthcare spending, an aging population, and the rise in lifestyle-related diseases. To that end, it could be wise to buy fundamentally strong medical stocks Medifast (MED) and Zynex (ZYXI). On the other hand, Herbalife (HLF) could be added to one’s…

Is Zynex (ZYXI) the Medical Stock to Buy?

Is Zynex (ZYXI) the Medical Stock to Buy?

Medical devices provider Zynex (ZYXI) delivered strong topline growth in the last quarter and hopes to continue that momentum throughout fiscal 2023. Is the stock a good portfolio addition now? Let’s look at some of its key financial metrics….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Zynex Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Zynex (NASDAQ:ZYXI) earned $1.38 million, a 84.52% increase from the preceding quarter. Zynex's sales decreased to $31.08 million, a 23.0% change since Q4.

Zynex Tightens Q1 Sales, EBITDA Guidance; CM-1600 Blood & Fluid Monitor Awaits FDA Approval

Zynex Inc (NASDAQ:ZYXI) expects Q1 FY22 sales of $30.5 million - $31.5 million, approximately 26% higher than Q1 2021, in line with the consensus of $31.04 million. Earlier, the Company had forecasted sales of $29 million - $32 million. The Company expects adjusted EBITDA between $3 million - $4 million versus the prior…

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More

Here's a roundup of top developments in the biotech space over the last 24 hours.

Zynex: Q4 Earnings Insights

Zynex (NASDAQ:ZYXI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Zynex beat estimated earnings by 15.0%, reporting an EPS of $0.23 versus an estimate of $0.2.

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: Zynex

Earnings Preview: Zynex

Zynex (NASDAQ:ZYXI) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Zynex will report an earnings per share (EPS) of $0.20.

1

People

Dipanjan BanchurSince

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Cardinal Health

BristolMyers Squibb

Cardinal Health Inc

Wake Forest University

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

355,335 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play